CEO Matthew Weinberg Presents at FDA Clinical Trials Hearing

April 23, 2012

April 23 - The Weinberg Group CEO, Matthew Weinberg, presented today at FDA’s hearing titled “Modernizing the Regulation of Clinical Trials and Approaches to Good Clinical Practice.”  Mr. Weinberg presented on the mandatory need for audits and audit independence.  A full copy of his presentation can be found below.

For more information on The Weinberg Group’s independent clinical auditing services, please contact
Jeff Antos, Vice President, at jeff.antos@weinberggroup.com or 202.280.0815.

TAGS:

Related Articles

April 17, 2018

The Weinberg Group CEO to Speak at AIPPI’s International Convention on the Economy of Innovation

WASHINGTON, DC – April 17, 2018 – Matthew Weinberg, Chief Executive Officer of The Weinberg Group Inc., will be speaking at the International Association for the Protection of Intellectual Property’s...

Continue reading the blog post

November 25, 2014

Matthew Weinberg Quoted in Article about EMA’s Initiative to Broaden Expert Involvement with Updated Policy on Conflicts of Interest

FDANews Drug Industry Daily Nov. 21, 2014 Europe’s drug regulatory agency has revised the conflict of interest policy for its scientific committee members and experts, a move that one attorney says...

Continue reading the blog post

June 17, 2014

Matthew Weinberg Writes for Tobacco Reporter

CEO Matthew Weinberg writes for Tobacco Reporter Magazine encouraging stakeholders to take advantage of the opportunity to respond to FDA e-cigarette regulations.

Continue reading the blog post